カテゴリー： Market Monitor Global, 世界, 医療/バイオ

代謝障害治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Metabolic Disorders Drugs Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5763）

◆商品コード：MMG23JU5763
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月（※2025年版があります。お問い合わせください。）
◆ページ数：70
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Metabolic Disorders Drugs Market 調査レポートは次の情報を含め、グローバルにおけるの代謝障害治療薬市場規模と予測を収録しています。・世界の代謝障害治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の代謝障害治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の代謝障害治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「グリコーゲン代謝疾患治療薬」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

代謝障害治療薬のグローバル主要企業は、Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Boehringer Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharmaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、代謝障害治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の代謝障害治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の代謝障害治療薬市場：タイプ別市場シェア、2022年
・グリコーゲン代謝疾患治療薬、脂質代謝疾患治療薬、アミノ酸代謝疾患治療薬、その他

世界の代謝障害治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の代謝障害治療薬市場：用途別市場シェア、2022年
・病院、小売薬局

世界の代謝障害治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の代謝障害治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における代謝障害治療薬のグローバル売上、2018年-2023年
・主要企業における代謝障害治療薬のグローバル売上シェア、2022年
・主要企業における代謝障害治療薬のグローバル販売量、2018年-2023年
・主要企業における代謝障害治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Boehringer Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharma

*************************************************************

・調査・分析レポートの概要
代謝障害治療薬市場の定義
市場セグメント
世界の代謝障害治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の代謝障害治療薬市場規模
世界の代謝障害治療薬市場規模：2022年 VS 2029年
世界の代謝障害治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの代謝障害治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の代謝障害治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：グリコーゲン代謝疾患治療薬、脂質代謝疾患治療薬、アミノ酸代謝疾患治療薬、その他
代謝障害治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、小売薬局
代謝障害治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別代謝障害治療薬市場規模 2022年と2029年
地域別代謝障害治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Boehringer Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharma
...

Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
This report aims to provide a comprehensive presentation of the global market for Metabolic Disorders Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disorders Drugs. This report contains market size and forecasts of Metabolic Disorders Drugs in global, including the following market information:
Global Metabolic Disorders Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Metabolic Disorders Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Metabolic Disorders Drugs companies in 2022 (%)
The global Metabolic Disorders Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Glycogen Metabolism Disease Drug Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Metabolic Disorders Drugs include Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin and LG Life Science, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Metabolic Disorders Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metabolic Disorders Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Metabolic Disorders Drugs Market Segment Percentages, by Type, 2022 (%)
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
Global Metabolic Disorders Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Metabolic Disorders Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Global Metabolic Disorders Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Metabolic Disorders Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metabolic Disorders Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Metabolic Disorders Drugs revenues share in global market, 2022 (%)
Key companies Metabolic Disorders Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Metabolic Disorders Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Boehringer Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Metabolic Disorders Drugs, market overview.
Chapter 2: Global Metabolic Disorders Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Metabolic Disorders Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Metabolic Disorders Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Metabolic Disorders Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Metabolic Disorders Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Metabolic Disorders Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Metabolic Disorders Drugs Overall Market Size
2.1 Global Metabolic Disorders Drugs Market Size: 2022 VS 2029
2.2 Global Metabolic Disorders Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Metabolic Disorders Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Metabolic Disorders Drugs Players in Global Market
3.2 Top Global Metabolic Disorders Drugs Companies Ranked by Revenue
3.3 Global Metabolic Disorders Drugs Revenue by Companies
3.4 Global Metabolic Disorders Drugs Sales by Companies
3.5 Global Metabolic Disorders Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Metabolic Disorders Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Metabolic Disorders Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Metabolic Disorders Drugs Players in Global Market
3.8.1 List of Global Tier 1 Metabolic Disorders Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Metabolic Disorders Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Metabolic Disorders Drugs Market Size Markets, 2022 & 2029
4.1.2 Glycogen Metabolism Disease Drug
4.1.3 Lipid Metabolism Disease Drug
4.1.4 Amino Acid Metabolism Drug
4.1.5 Other
4.2 By Type – Global Metabolic Disorders Drugs Revenue & Forecasts
4.2.1 By Type – Global Metabolic Disorders Drugs Revenue, 2018-2023
4.2.2 By Type – Global Metabolic Disorders Drugs Revenue, 2024-2029
4.2.3 By Type – Global Metabolic Disorders Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Metabolic Disorders Drugs Sales & Forecasts
4.3.1 By Type – Global Metabolic Disorders Drugs Sales, 2018-2023
4.3.2 By Type – Global Metabolic Disorders Drugs Sales, 2024-2029
4.3.3 By Type – Global Metabolic Disorders Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Metabolic Disorders Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Metabolic Disorders Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.2 By Application – Global Metabolic Disorders Drugs Revenue & Forecasts
5.2.1 By Application – Global Metabolic Disorders Drugs Revenue, 2018-2023
5.2.2 By Application – Global Metabolic Disorders Drugs Revenue, 2024-2029
5.2.3 By Application – Global Metabolic Disorders Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Metabolic Disorders Drugs Sales & Forecasts
5.3.1 By Application – Global Metabolic Disorders Drugs Sales, 2018-2023
5.3.2 By Application – Global Metabolic Disorders Drugs Sales, 2024-2029
5.3.3 By Application – Global Metabolic Disorders Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Metabolic Disorders Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Metabolic Disorders Drugs Market Size, 2022 & 2029
6.2 By Region – Global Metabolic Disorders Drugs Revenue & Forecasts
6.2.1 By Region – Global Metabolic Disorders Drugs Revenue, 2018-2023
6.2.2 By Region – Global Metabolic Disorders Drugs Revenue, 2024-2029
6.2.3 By Region – Global Metabolic Disorders Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Metabolic Disorders Drugs Sales & Forecasts
6.3.1 By Region – Global Metabolic Disorders Drugs Sales, 2018-2023
6.3.2 By Region – Global Metabolic Disorders Drugs Sales, 2024-2029
6.3.3 By Region – Global Metabolic Disorders Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Metabolic Disorders Drugs Revenue, 2018-2029
6.4.2 By Country – North America Metabolic Disorders Drugs Sales, 2018-2029
6.4.3 US Metabolic Disorders Drugs Market Size, 2018-2029
6.4.4 Canada Metabolic Disorders Drugs Market Size, 2018-2029
6.4.5 Mexico Metabolic Disorders Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Metabolic Disorders Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Metabolic Disorders Drugs Sales, 2018-2029
6.5.3 Germany Metabolic Disorders Drugs Market Size, 2018-2029
6.5.4 France Metabolic Disorders Drugs Market Size, 2018-2029
6.5.5 U.K. Metabolic Disorders Drugs Market Size, 2018-2029
6.5.6 Italy Metabolic Disorders Drugs Market Size, 2018-2029
6.5.7 Russia Metabolic Disorders Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Metabolic Disorders Drugs Market Size, 2018-2029
6.5.9 Benelux Metabolic Disorders Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Metabolic Disorders Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Metabolic Disorders Drugs Sales, 2018-2029
6.6.3 China Metabolic Disorders Drugs Market Size, 2018-2029
6.6.4 Japan Metabolic Disorders Drugs Market Size, 2018-2029
6.6.5 South Korea Metabolic Disorders Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Metabolic Disorders Drugs Market Size, 2018-2029
6.6.7 India Metabolic Disorders Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Metabolic Disorders Drugs Revenue, 2018-2029
6.7.2 By Country – South America Metabolic Disorders Drugs Sales, 2018-2029
6.7.3 Brazil Metabolic Disorders Drugs Market Size, 2018-2029
6.7.4 Argentina Metabolic Disorders Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Metabolic Disorders Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Metabolic Disorders Drugs Sales, 2018-2029
6.8.3 Turkey Metabolic Disorders Drugs Market Size, 2018-2029
6.8.4 Israel Metabolic Disorders Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Metabolic Disorders Drugs Market Size, 2018-2029
6.8.6 UAE Metabolic Disorders Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Metabolic Disorders Drugs Major Product Offerings
7.1.4 Merck Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Metabolic Disorders Drugs Major Product Offerings
7.2.4 Novartis Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Takeda Pharmaceutical
7.3.1 Takeda Pharmaceutical Company Summary
7.3.2 Takeda Pharmaceutical Business Overview
7.3.3 Takeda Pharmaceutical Metabolic Disorders Drugs Major Product Offerings
7.3.4 Takeda Pharmaceutical Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Takeda Pharmaceutical Key News & Latest Developments
7.4 Astra Zeneca
7.4.1 Astra Zeneca Company Summary
7.4.2 Astra Zeneca Business Overview
7.4.3 Astra Zeneca Metabolic Disorders Drugs Major Product Offerings
7.4.4 Astra Zeneca Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Astra Zeneca Key News & Latest Developments
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Company Summary
7.5.2 Boehringer Ingelheim Business Overview
7.5.3 Boehringer Ingelheim Metabolic Disorders Drugs Major Product Offerings
7.5.4 Boehringer Ingelheim Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Boehringer Ingelheim Key News & Latest Developments
7.6 KOWA
7.6.1 KOWA Company Summary
7.6.2 KOWA Business Overview
7.6.3 KOWA Metabolic Disorders Drugs Major Product Offerings
7.6.4 KOWA Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.6.5 KOWA Key News & Latest Developments
7.7 Kythera
7.7.1 Kythera Company Summary
7.7.2 Kythera Business Overview
7.7.3 Kythera Metabolic Disorders Drugs Major Product Offerings
7.7.4 Kythera Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Kythera Key News & Latest Developments
7.8 Fuji yakuhin
7.8.1 Fuji yakuhin Company Summary
7.8.2 Fuji yakuhin Business Overview
7.8.3 Fuji yakuhin Metabolic Disorders Drugs Major Product Offerings
7.8.4 Fuji yakuhin Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Fuji yakuhin Key News & Latest Developments
7.9 LG Life Science
7.9.1 LG Life Science Company Summary
7.9.2 LG Life Science Business Overview
7.9.3 LG Life Science Metabolic Disorders Drugs Major Product Offerings
7.9.4 LG Life Science Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.9.5 LG Life Science Key News & Latest Developments
7.10 Metsubishi Tanabe Pharma
7.10.1 Metsubishi Tanabe Pharma Company Summary
7.10.2 Metsubishi Tanabe Pharma Business Overview
7.10.3 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Major Product Offerings
7.10.4 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Metsubishi Tanabe Pharma Key News & Latest Developments
8 Global Metabolic Disorders Drugs Production Capacity, Analysis
8.1 Global Metabolic Disorders Drugs Production Capacity, 2018-2029
8.2 Metabolic Disorders Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Metabolic Disorders Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Metabolic Disorders Drugs Supply Chain Analysis
10.1 Metabolic Disorders Drugs Industry Value Chain
10.2 Metabolic Disorders Drugs Upstream Market
10.3 Metabolic Disorders Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Metabolic Disorders Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Metabolic Disorders Drugs in Global Market
Table 2. Top Metabolic Disorders Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Metabolic Disorders Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Metabolic Disorders Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Metabolic Disorders Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Metabolic Disorders Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Metabolic Disorders Drugs Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Metabolic Disorders Drugs Product Type
Table 9. List of Global Tier 1 Metabolic Disorders Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Metabolic Disorders Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Metabolic Disorders Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Metabolic Disorders Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Metabolic Disorders Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Metabolic Disorders Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Metabolic Disorders Drugs Sales (K Units), 2024-2029
Table 16. By Application – Global Metabolic Disorders Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Metabolic Disorders Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Metabolic Disorders Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Metabolic Disorders Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Metabolic Disorders Drugs Sales (K Units), 2024-2029
Table 21. By Region – Global Metabolic Disorders Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Metabolic Disorders Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Metabolic Disorders Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Metabolic Disorders Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Metabolic Disorders Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Metabolic Disorders Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Metabolic Disorders Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Metabolic Disorders Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Metabolic Disorders Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Metabolic Disorders Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Metabolic Disorders Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Metabolic Disorders Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Metabolic Disorders Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Metabolic Disorders Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Metabolic Disorders Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Metabolic Disorders Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Metabolic Disorders Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Metabolic Disorders Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Metabolic Disorders Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Metabolic Disorders Drugs Sales, (K Units), 2024-2029
Table 46. Merck Company Summary
Table 47. Merck Metabolic Disorders Drugs Product Offerings
Table 48. Merck Metabolic Disorders Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Merck Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Metabolic Disorders Drugs Product Offerings
Table 52. Novartis Metabolic Disorders Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Novartis Key News & Latest Developments
Table 54. Takeda Pharmaceutical Company Summary
Table 55. Takeda Pharmaceutical Metabolic Disorders Drugs Product Offerings
Table 56. Takeda Pharmaceutical Metabolic Disorders Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Takeda Pharmaceutical Key News & Latest Developments
Table 58. Astra Zeneca Company Summary
Table 59. Astra Zeneca Metabolic Disorders Drugs Product Offerings
Table 60. Astra Zeneca Metabolic Disorders Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Astra Zeneca Key News & Latest Developments
Table 62. Boehringer Ingelheim Company Summary
Table 63. Boehringer Ingelheim Metabolic Disorders Drugs Product Offerings
Table 64. Boehringer Ingelheim Metabolic Disorders Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Boehringer Ingelheim Key News & Latest Developments
Table 66. KOWA Company Summary
Table 67. KOWA Metabolic Disorders Drugs Product Offerings
Table 68. KOWA Metabolic Disorders Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. KOWA Key News & Latest Developments
Table 70. Kythera Company Summary
Table 71. Kythera Metabolic Disorders Drugs Product Offerings
Table 72. Kythera Metabolic Disorders Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Kythera Key News & Latest Developments
Table 74. Fuji yakuhin Company Summary
Table 75. Fuji yakuhin Metabolic Disorders Drugs Product Offerings
Table 76. Fuji yakuhin Metabolic Disorders Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Fuji yakuhin Key News & Latest Developments
Table 78. LG Life Science Company Summary
Table 79. LG Life Science Metabolic Disorders Drugs Product Offerings
Table 80. LG Life Science Metabolic Disorders Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. LG Life Science Key News & Latest Developments
Table 82. Metsubishi Tanabe Pharma Company Summary
Table 83. Metsubishi Tanabe Pharma Metabolic Disorders Drugs Product Offerings
Table 84. Metsubishi Tanabe Pharma Metabolic Disorders Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Metsubishi Tanabe Pharma Key News & Latest Developments
Table 86. Metabolic Disorders Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 87. Global Metabolic Disorders Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 88. Global Metabolic Disorders Drugs Production by Region, 2018-2023 (K Units)
Table 89. Global Metabolic Disorders Drugs Production by Region, 2024-2029 (K Units)
Table 90. Metabolic Disorders Drugs Market Opportunities & Trends in Global Market
Table 91. Metabolic Disorders Drugs Market Drivers in Global Market
Table 92. Metabolic Disorders Drugs Market Restraints in Global Market
Table 93. Metabolic Disorders Drugs Raw Materials
Table 94. Metabolic Disorders Drugs Raw Materials Suppliers in Global Market
Table 95. Typical Metabolic Disorders Drugs Downstream
Table 96. Metabolic Disorders Drugs Downstream Clients in Global Market
Table 97. Metabolic Disorders Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Metabolic Disorders Drugs Segment by Type in 2022
Figure 2. Metabolic Disorders Drugs Segment by Application in 2022
Figure 3. Global Metabolic Disorders Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Metabolic Disorders Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Metabolic Disorders Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Metabolic Disorders Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Metabolic Disorders Drugs Revenue in 2022
Figure 9. By Type - Global Metabolic Disorders Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Metabolic Disorders Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Metabolic Disorders Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Metabolic Disorders Drugs Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Metabolic Disorders Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Metabolic Disorders Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Metabolic Disorders Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Metabolic Disorders Drugs Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Metabolic Disorders Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Metabolic Disorders Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Metabolic Disorders Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Metabolic Disorders Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Metabolic Disorders Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Metabolic Disorders Drugs Sales Market Share, 2018-2029
Figure 23. US Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Metabolic Disorders Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Metabolic Disorders Drugs Sales Market Share, 2018-2029
Figure 28. Germany Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Metabolic Disorders Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Metabolic Disorders Drugs Sales Market Share, 2018-2029
Figure 37. China Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Metabolic Disorders Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Metabolic Disorders Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Metabolic Disorders Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Metabolic Disorders Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Metabolic Disorders Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Metabolic Disorders Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Metabolic Disorders Drugs by Region, 2022 VS 2029
Figure 54. Metabolic Disorders Drugs Industry Value Chain
Figure 55. Marketing Channels

※参考情報

代謝障害治療薬は、体内の代謝機能に異常が生じることによって引き起こされる様々な疾患を治療するために使用される医薬品です。代謝は体内での化学反応の総称であり、栄養素の分解やエネルギーの生成、老廃物の排出など、生命維持に不可欠なプロセスです。代謝障害が生じると、これらのプロセスが正常に機能しなくなり、肥満、糖尿病、脂質異常症、甲状腺疾患など、幅広い健康問題が引き起こされます。ここでは、代謝障害治療薬の概念、特徴、種類、用途、関連技術などについて詳しく述べます。

まず、代謝障害治療薬の定義について考えます。代謝障害治療薬とは、代謝異常によって発症する各種疾患に特化した治療を目的とした医薬品です。これらの薬は、酵素の活性を調整したり、ホルモンの分泌を促進したり、栄養素の利用を改善したりすることで、代謝のバランスを正常に戻すことを目的としています。

代謝障害治療薬の特徴の一つに、治療対象となる疾患の多様性があります。例えば、糖尿病治療薬はインスリンの分泌を促進したり、インスリンの効果を高めたりします。また、脂質低下薬は血中のコレステロールや中性脂肪の値を下げることを目的としています。さらに、甲状腺ホルモン剤は甲状腺機能亢進症や低下症の治療に用いられます。このように、代謝障害治療薬は疾患の種類に応じて特異的に設計されています。

次に、代謝障害治療薬の種類について具体的に見ていきましょう。糖尿病治療薬には、経口薬とインスリン注射が含まれます。経口薬には、ビグアナイド系（メトホルミン）、スルホニル尿素系、DPP-4阻害薬、SGLT2阻害薬などが存在します。これらはそれぞれ異なるメカニズムで血糖をコントロールします。メトホルミンは肝臓でのグルコース産生を抑制し、スルホニル尿素系は膵臓からのインスリン分泌を促進する作用があります。

脂質異常症治療薬には、スタチン（HMG-CoA還元酵素阻害薬）、フィブラート系薬、ニコチン酸誘導体などが存在します。スタチンはコレステロール合成を抑制することで、LDLコレステロールを低下させます。フィブラート系薬は脂肪酸の酸化を促進することにより、トリグリセリドの減少を目指します。

甲状腺疾患に関連する治療薬には、甲状腺ホルモン薬（レボチロキシンなど）や抗甲状腺薬（メチマゾールなど）が含まれます。これらの薬は、ホルモンの不足や過剰を調整する役割を果たします。

次に、代謝障害治療薬の用途について説明します。これらの薬は、主に以下のような用途があります。1つ目は、糖尿病の管理です。血糖値を適切にコントロールすることで、急激な合併症を防ぎ、生活の質を向上させることができます。2つ目は、脂質異常症の改善です。心血管疾患のリスクを低下させるために、血中の脂質レベルを正常化することが重要です。3つ目は、甲状腺機能の調整です。甲状腺ホルモンが過剰または不足している場合、身体全体の代謝が影響を受けるため、適切な治療が求められます。

代謝障害治療薬に関連する技術は、現在も進化を続けています。特に、個別化医療の進展が挙げられます。遺伝子情報や生活習慣に基づいた治療方針の構築が進むことで、患者一人ひとりに適した治療法が提供されるようになっています。また、デジタルヘルスの普及により、血糖値や体重管理のためのアプリやデバイスが活用され、患者の自己管理能力が向上しています。

さらに、治療薬の開発においては、バイオ医薬品や新しい化合物の探索が進められています。遺伝子治療や細胞治療、モノクローナル抗体によるアプローチなど、新しい技術が代謝障害に新たな治療の可能性をもたらしています。

まとめると、代謝障害治療薬は、代謝に関連するさまざまな疾患を治療するための重要な医薬品です。その特徴や種類は多岐にわたり、糖尿病、脂質異常症、甲状腺疾患など、各疾患に応じた特異的なアプローチが求められています。新興技術の進化により、より効果的かつ個別化された治療が可能となり、今後の代謝障害治療薬の発展が期待されます。健康的な生活を維持するためには、これらの薬剤の適切な使用と、生活習慣の改善が不可欠です。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 代謝障害治療薬の世界市場見通し2023年-2029年(Metabolic Disorders Drugs Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

代謝障害治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp